1. Search Result
Search Result
Results for "

S. aureus

" in MedChemExpress (MCE) Product Catalog:

223

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

58

Peptides

4

Inhibitory Antibodies

45

Natural
Products

25

Recombinant Proteins

14

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14926

    (S)-(-)-Nadifloxacin; WCK 771

    Antibiotic Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
    Levonadifloxacin
  • HY-E70234

    SrtA

    Others Others
    Sortase A, S. aureus (SrtA), a transpeptidase enzyme is present in many Gram-positive bacteria and helps in the recruitment of the cell surface proteins. Sortase A, S. aureus plays an important part in ligation of various molecules on the cell surfaces .
    Sortase A, <em>S</em>. <em>aureus</em>
  • HY-N3623

    Bacterial Infection
    Corianin is a sesquiterpene lactone that can be isolated from the fruits of Coriaria ruscifolia. Corianin shows antibacterial activity against S. aureus and S. epidermis .
    Corianin
  • HY-107222

    Others Inflammation/Immunology
    Lysionotin is a flavonoid isolated from Gesneriaceae family. Lysionotin efficiently inhibit α-Toxin (a pore-forming protein) expression and shows significant protection against S. aureus in vitro and in vivo. Lysionotin has the potential for the treatment of S. aureus induced pneumonia .
    Lysionotin
  • HY-135184

    CBR-2092; TNP-2092

    Antibiotic Bacterial DNA/RNA Synthesis Infection
    Rifaquizinone (CBR-2092) is a Rifamycin-Quinolone Hybrid Antibiotic. Rifaquizinone inhibits wild-type S. aureus RNA polymerase with an IC50 of 34 nM. Rifaquizinone is effective against S. aureus infections, with MICs ranged from 0.008 to 0.5 μg/mL for 300 clinical isolates of staphylococci and streptococci .
    Rifaquizinone
  • HY-N10986

    Bacterial Infection Inflammation/Immunology
    (±)-Hydnocarpin is a flavonolignan. (±)-Hydnocarpin can inhibit the growth of S. aureus with a MIC50 value of 3.1 μM .
    (±)-Hydnocarpin
  • HY-146458

    Bacterial Cytochrome P450 Infection
    Antibacterial agent 102 (compound 32) possesses potent in vitro and in vivo antibacterial activity, with MICs < 0.5 μg/mL in Staphylococcus aureus (S. aureus). Antibacterial agent 102 also moderately inhibits CYP3A4 with an IC50 value of 6.148 μM. Antibacterial agent 102 can reduce Methicillin-resistant Staphylococcus aureus (MRSA) load in thigh infected mice .
    Antibacterial agent 102
  • HY-P4200

    Antibiotic Bacterial Infection
    Lugdunin is an antibiotic peptide. Lugdunin inhibits bacteria by dissipating their membrane potential. Lugdunin is active against Gram-positive bacteria, such as S. aureus, and reduces S. aureus skin and nasal colonization. Lugdunin induces LL-37 and CXCL8/MIP-2 in human keratinocytes and mouse skin .
    Lugdunin
  • HY-14784

    REP8839

    Bacterial Infection
    Bederocin (REP8839) is a Methionyl-tRNA synthetase inhibitor. Bederocin can be used in research of bacterial infection, including S. aureus and MRSA .
    Bederocin
  • HY-P2576

    Bacterial Infection
    Polistes mastoparan is an antimicrobial peptide. Polistes mastoparan increases S. aureus cell K + efflux and inhibits cell viability with EC50 of 5 μM .
    Polistes mastoparan
  • HY-P99770

    514-G3

    Bacterial Infection
    Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
    Omodenbamab
  • HY-163098

    Fluorescent Dye Others
    JJ-OX-007 is a fluorescent probe which selectively for FphE in live S.aureus cells .
    JJ-OX-007
  • HY-156416

    Bacterial Infection
    LtaS-IN-2 (compound 13) is a inhibitor of LTA synthesis, and shows antibacterial activity against S. aureus and S. epidermidis, with the MIC90 of 0.5 μg/mL and 1 μg/mL, respectively. LtaS-IN-2 is a derivative of LtaS-IN-1 (HY-135813) .
    LtaS-IN-2
  • HY-P4204

    Bacterial Infection
    Ranalexin is an antimicrobial peptide. Ranalexin inhibits S. aureus, E. coli, P. aerugiaosa with MICs of 4, 32, 128 μg/mL .
    Ranalexin
  • HY-125424

    Bacterial Inflammation/Immunology
    AM8191 is an orally active bactericidal and selectively inhibits DNA synthesis and Staphylococcus aureus gyrase (IC50=1.02 μM) and topo IV (IC50=10.4 μM). AM8191 inhibits S. aureus MSSA (MIC=0.02 μg/mL) and S. aureus MRSA (MIC=0.06 μg/mL) .
    AM8191 hydrochloride
  • HY-130281

    Bacterial Inflammation/Immunology
    Ianthelliformisamine B diTFA is a bromotyrosine-derived antibacterial agent. Ianthelliformisamine B diTFA is against E. coli and S. aureus strains with MICs of 14.5 μM and 144.7 μM .
    Ianthelliformisamine B diTFA
  • HY-146591

    Bacterial Infection
    Antibacterial agent 87 (Compound 4h) is a potent antibacterial agent with MIC values of 0.125, 0.0625 and 0.0625 μg/mL against MRSA, MRSE and S. aureus, respectively .
    Antibacterial agent 87
  • HY-N12600

    Bacterial Infection
    Thiolopyrrolone A (compound 1) exhibits antibacterial activities against BCG, M. tuberculosis and S. aureus with minimum inhibitory concentrations (MIC) of 10, 10 and 100 μg/mL, respectively .
    Thiolopyrrolone A
  • HY-W354851

    Bacterial Antibiotic Infection
    Pisiferic acid is an antibacterial agent with inhibitory activity against Gram-negative/positive bacteria such as P. vulgaris, S. aureus and B. subtilis. Pisiferic acid can be used to study bacterial infections .
    Pisiferic acid
  • HY-146403

    Bacterial Infection
    Antibacterial agent 98 (compound g37) is a potent and orally active antibacterial agent. Antibacterial agent 98 inhibits the ATPase activity of Gyrase B and impairs Staphylococcus aureus (S. aureus ) DNA supercoiling. Antibacterial agent 98 shows antibacterial activity and not induce resistance development of MRSA (methicillin-resistant S. aureus) .
    Antibacterial agent 98
  • HY-P5625

    Bacterial Infection
    ROAD-1 is an oral mucosal α-defensin of Rhesus Macaque. ROAD-1 is active against S. aureus, E. coli, and C. albicans .
    ROAD-1
  • HY-16911
    AFN-1252
    Maximum Cited Publications
    6 Publications Verification

    API-1252; Debio 1452

    Bacterial Antibiotic Infection
    AFN-1252 is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 exhibits typical MIC90 values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith .
    AFN-1252
  • HY-146503

    Bacterial Infection
    Antibacterial agent 86 (Compound A11) is the most active and displays bacteriostatic activities against methicillin-resistant S. aureus, with MIC values as low as 0.00191 μg/mL, which is 162 and 32 times lower than that of the marketed antibiotics tiamulin and retapamulin, respectively .
    Antibacterial agent 86
  • HY-N1673

    Gentisaldehyde

    Bacterial Infection
    2,5-Dihydroxybenzaldehyde (Gentisaldehyde) is a naturally occurring antimicrobial that inhibits the growth of Mycobacterium avium subsp. paratuberculosis. 2,5-Dihydroxybenzaldehyde is active against S. aureus strains with a MIC50 of 500 mg/L .
    2,5-Dihydroxybenzaldehyde
  • HY-152097

    ClpP Bacterial Infection
    (S)-ZG197 is a highly selective Staphylococcus aureus Caseinolytic protease P (SaClpP) activator with an EC50 of 1.4 μM .
    (S)-ZG197
  • HY-146593

    Bacterial Infection
    Antibacterial agent 88 (Compound 5h) is a potent antibacterial agent with MIC values of both ≤0.0156 μg/mL against MRSA, MRSE and S. aureus. Antibacterial agent 88 also inhibits B. subtilis with an MIC of 4 μg/mL .
    Antibacterial agent 88
  • HY-N2417

    Bacterial Infection
    Stearyl glycyrrhetinate, a major component in licorice extract, has a MIC against S. aureus strains of more than 256 mg/L. Stearyl glycyrrhetinate has antibacterial effects .
    Stearyl glycyrrhetinate
  • HY-P99551

    KBSA301; AR-301

    Antibiotic Infection
    Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
    Tosatoxumab
  • HY-P99583

    MEDI4893

    Bacterial Infection Inflammation/Immunology
    Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
    Suvratoxumab
  • HY-B0975

    Phenoxymethylpenicillin potassium salt

    Bacterial Antibiotic Infection
    Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .
    Penicillin V Potassium
  • HY-157143

    Bacterial Infection
    Antibacterial agent 164 (compound 2a) is an antibacterial and antibiofilm agent. Antibacterial agent 164 inhibits S. aureus and B. subtilis (MIC of 0.09 mM), and also exhibits strong anti-B. Subtilis biofilm formation .
    Antibacterial agent 164
  • HY-B0536

    AM-1091; CI-960; PD 127391

    Bacterial Antibiotic Infection
    Clinafloxacin (AM 1091) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro . Clinafloxacin is against DNA gyrase and topoisomerase IV of S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively .
    Clinafloxacin
  • HY-B0536A

    AM 1091 hydrochloride; CI 960 hydrochloride; PD127391 hydrochloride

    Bacterial Antibiotic Infection
    Clinafloxacin hydrochloride (AM 1091 hydrochloride) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro . Clinafloxacin hydrochloride is against DNA gyrase and topoisomerase IV of S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively .
    Clinafloxacin hydrochloride
  • HY-B0466
    Cloxacillin sodium monohydrate
    3 Publications Verification

    Beta-lactamase Bacterial Antibiotic Infection Inflammation/Immunology Cancer
    Cloxacillin sodium monohydrate is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 µM. Cloxacillin sodium monohydrate can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
    Cloxacillin sodium monohydrate
  • HY-B0466B
    Cloxacillin sodium
    3 Publications Verification

    Beta-lactamase Bacterial Antibiotic Infection Inflammation/Immunology Cancer
    Cloxacillin sodium is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 µM. Cloxacillin sodium can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
    Cloxacillin sodium
  • HY-B0466A

    Beta-lactamase Antibiotic Bacterial Infection Inflammation/Immunology Cancer
    Cloxacillin is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 µM. Cloxacillin can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
    Cloxacillin
  • HY-N10087A

    Bacterial Infection
    Angustifoline hydrochloride, an alkaloid, can be isolated from Lupinus angustifolius L. alkaloid extract. Angustifoline hydrochloride exhibits antimicrobial activity. Angustifoline hydrochloride could have bacteriostatic effects against S. aureusB. subtilisE. coliP. aeruginosa and B. thuringiensis .
    Angustifoline hydrochloride
  • HY-155282

    Fatty Acid Synthase (FASN) Bacterial Inflammation/Immunology
    FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively .
    FASN-IN-6
  • HY-P5836

    Interleukin Related Bacterial Enterovirus Inflammation/Immunology
    Citrullinated LL-37 1cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 1cit does not alter the antiviral effect of LL-37 toward human rhinovirus. Citrullinated LL-37 1cit shows antibacterial activity toward S. aureus. Citrullinated LL-37 1cit causes a reduction in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B .
    Citrullinated LL-37 1cit
  • HY-B0097
    Floxuridine
    3 Publications Verification

    5-Fluorouracil 2'-deoxyriboside

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis Infection Cancer
    Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .
    Floxuridine
  • HY-147522

    Bacterial Antibiotic Infection Cancer
    ADG-2e is a potent antibacterial agent with MICs of 16, 4, 2, and 2 μg/mL for E. coli [KCTC 1682], P. aeruginosa [KCTC 1637], B.subtilis [KCTC 3068], and S. aureus [KCTC 1621], respectively. ADG-2e shows anti-metastatic activity against breast cancer cells .
    ADG-2e
  • HY-N12096

    α-Acetylsalazinic acid

    Bacterial Infection
    Galbinic acid (α-Acetylsalazinic acid), a lichen acid, shows antibacterial activities against the Gram-positive bacteria B. cereus, B. subtilis, and S. aureus (MICs=62.5, 62.5, 250 μg/ml, respectively). Galbinic acid inhibits the Gram-negative bacterium E. coli (MIC=125 μg/ml) .
    Galbinic acid
  • HY-162273

    Bacterial Smo Gli Infection Cancer
    Antibacterial agent 189 (compound 3a) is a potent antimicrobial agent. Antibacterial agent 189 offers high binding energy against the target OMPA/exo-1,3-beta-glucanase proteins. Antibacterial agent 189 exhibits the potent antimicrobial activities against E. coli, P. aeruginosa, S. aureus, B. subtilis, C. Albicans and A. flavus. Antibacterial agent 189 shows high binding energy against target SMO and SUFU/GLI-1 proteins .
    Antibacterial agent 189
  • HY-10581A
    Gatifloxacin hydrochloride
    3 Publications Verification

    AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin hydrochloride
  • HY-10581B

    AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin mesylate
  • HY-10581
    Gatifloxacin
    3 Publications Verification

    AM-1155; BMS-206584; PD135432

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin
  • HY-10581C

    AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate

    Bacterial Topoisomerase Antibiotic Infection Inflammation/Immunology
    Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin sesquihydrate
  • HY-16115

    Others Metabolic Disease
    BPH-652 is a S. aureus dehydrosqualene synthase (CrtM) inhibitor, with a Ki of 1.5 nM and an IC50 of 100-300 nM (S. aureus pigment formation) .
    BPH-652
  • HY-P3349

    Bacterial Infection
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal] (Compound 9C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 25 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal]
  • HY-P3348

    Bacterial Infection
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip] (Compound 8C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 12.5 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip]

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: